In this sense, OPB-51602, the small-molecule inhibitor of STAT3 phosphorylation was evaluated in phase I (NCT01423903) multiple dose escalation clinical trial to determine safety and tolerability in subjects with advanced cancers for whom there is no standard treatment available. The gene discussed is STAT3; the disease is cancer.